Rigel Pharmaceuticals (RIGL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Sales | 55,307 | 36,841 | 29,534 | 35,792 | 28,134 |
| Cost of Goods | 8,026 | 2,807 | 2,025 | 3,790 | 1,268 |
| Gross Profit | 47,281 | 34,034 | 27,509 | 32,002 | 26,866 |
| Operating Expenses | 33,251 | 34,394 | 34,500 | 30,826 | 31,599 |
| Operating Income | 14,056 | 447 | -6,966 | 1,966 | -4,465 |
| Interest Expense | 2,060 | 2,029 | 1,874 | 1,907 | 1,899 |
| Other Income | 425 | 552 | 593 | 678 | 672 |
| Pre-tax Income | 12,421 | -1,030 | -8,247 | 737 | -5,692 |
| Net Income Continuous | 12,421 | -1,030 | -8,247 | 737 | -5,692 |
| Net Income | $12,421 | $-1,030 | $-8,247 | $737 | $-5,692 |
| EPS Basic Total Ops | 0.71 | -0.06 | -0.47 | 0.07 | -0.33 |
| EPS Basic Continuous Ops | 0.71 | -0.06 | -0.47 | 0.04 | -0.33 |
| EPS Diluted Total Ops | 0.70 | -0.06 | -0.47 | 0.07 | -0.33 |
| EPS Diluted Continuous Ops | 0.70 | -0.06 | -0.47 | 0.04 | -0.33 |
| EPS Diluted Before Non-Recurring Items | 0.70 | -0.06 | -0.50 | N/A | N/A |
| EBITDA(a) | $14,598 | $901 | $-6,771 | $1,999 | $-4,278 |